TYSABRI®

(Natalizumab)

Documentation

Patented
Approved 2004
FDA Letter
FDA Label
Full Sequence

Brief Summary

Function Type: Antagonist
Target: Integrin-α4
Indication Category: Autoimmunity

Approved Indications

Detailed Summary

Side Effects

References

Wikipedia
Drugs.com
FDA